Document Top

Back to Lung Cancer

Summary of first-line Avastin-based therapy: consistently proven to give patients more time without PD

Avastin first line: proven to deliver the longest survival time in non-squamous(Pertaining to cells not from squamous epithelium; relatively common, locally invasive and occasionally metastatic) NSCLC and give patients more time without PD

Precise VEGF(A protein that promotes angiogenesis and is known to be a prognostic factor in several types of tumour) inhibition with Avastin maintains control of tumour(An abnormal growth of cells, forming a mass of tissue) growth and metastasis(The spread of a disease from one organ or part to another non-adjacent organ or part).

Avastin-based therapy extends survival beyond that achieved with conventional chemotherapy, with OS(The time from trial entry to death from any cause) beyond 1 year

  • Unprecedented OS of 14.2 months in adenocarcinoma(Cancer of the epithelium that originates in glandular tissue) patients (ECOG 4599).1
  • Median OS of 14.6 months in the overall population (SAiL).2

Avastin significantly and consistently improves PFS(The time from trial entry to disease progression or death from any cause) across patient subgroups (AVAiL and ECOG 4599).3,4

Based on the established need for angiogenesis(The growth of new blood vessels from pre-existing vessels) inhibition throughout the course of the disease, an extensive trial programme is examining possible first-line combination therapies with Avastin (including Avastin plus Tarceva).

References

  1. Sandler A, Yi J, Dahlberg S, Kolb MM, et al. J Thorac Oncol 2010;5:1416–23.
  2. Crinò L, Dansin E, Garrido P, et al. Lancet Oncol 2010;11:733–40.
  3. Reck M, von Pawel J, Zatloukal P, et al. J Clin Oncol 2009;27:1227–34.
  4. Sandler A, Gray R, Perry MC, et al. N Engl J Med 2006;355:2542–50.

Back to Lung Cancer Back to top

x

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.

OK Cancel